Ditchcarbon
  • Contact
  1. Organizations
  2. Nexus Pharmaceuticals, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated a month ago

Nexus Pharmaceuticals, Inc. Sustainability Profile

Company website

Nexus Pharmaceuticals, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2014, the company has rapidly established itself as a leader in the development and manufacturing of high-quality injectable medications. With a focus on complex generics and specialty pharmaceuticals, Nexus Pharmaceuticals is dedicated to addressing unmet medical needs through innovative solutions. The company’s core product offerings include a range of sterile injectable drugs that are distinguished by their quality and reliability. Nexus Pharmaceuticals has achieved significant milestones, including FDA approvals for several key products, solidifying its position in the competitive pharmaceutical landscape. With a commitment to excellence and patient safety, Nexus Pharmaceuticals continues to expand its operational reach, contributing to improved healthcare outcomes globally.

DitchCarbon Score

How does Nexus Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

23

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Nexus Pharmaceuticals, Inc.'s score of 23 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.

34%

Let us know if this data was useful to you

Nexus Pharmaceuticals, Inc.'s reported carbon emissions

Nexus Pharmaceuticals, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Nexus Pharmaceuticals may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives at this time. As the company operates within a sector increasingly focused on sustainability, it may benefit from developing and communicating clear climate commitments to align with industry trends and stakeholder expectations.

How Carbon Intensive is Nexus Pharmaceuticals, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Nexus Pharmaceuticals, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Nexus Pharmaceuticals, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Nexus Pharmaceuticals, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Nexus Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Nexus Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Nexus Pharmaceuticals, Inc.'s Emissions with Industry Peers

Amgen

US
•
Pharmaceutical Preparation Manufacturing
Updated about 21 hours ago

Sagent Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Novartis

CH
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Apotex Corp.

US
•
Pharmaceutical Preparation Manufacturing
Updated 23 days ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 10 hours ago

Sandoz Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 22 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251031.5
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy